Published in Annu Rev Genomics Hum Genet on January 01, 2009
The genetics of ageing. Nature (2010) 12.08
Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature (2011) 3.56
Nuclear lamins. Cold Spring Harb Perspect Biol (2010) 2.22
Inhibition of Ras for cancer treatment: the search continues. Future Med Chem (2011) 2.14
Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria. Science (2013) 1.88
Mammalian SUN protein interaction networks at the inner nuclear membrane and their role in laminopathy disease processes. J Biol Chem (2009) 1.79
Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. Neurology (2013) 1.62
An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. Hum Mol Genet (2010) 1.26
Regulation of prelamin A but not lamin C by miR-9, a brain-specific microRNA. Proc Natl Acad Sci U S A (2012) 1.26
Direct synthesis of lamin A, bypassing prelamin a processing, causes misshapen nuclei in fibroblasts but no detectable pathology in mice. J Biol Chem (2010) 1.24
Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino-terminal heterozygous missense lamin A/C mutations. Clin Genet (2009) 1.21
Biogenesis of the Saccharomyces cerevisiae pheromone a-factor, from yeast mating to human disease. Microbiol Mol Biol Rev (2012) 1.13
Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes. Hum Mol Genet (2010) 1.13
A truncated lamin A in the Lmna -/- mouse line: implications for the understanding of laminopathies. Nucleus (2012) 1.13
Human ZMPSTE24 disease mutations: residual proteolytic activity correlates with disease severity. Hum Mol Genet (2012) 1.11
Farnesylation of lamin B1 is important for retention of nuclear chromatin during neuronal migration. Proc Natl Acad Sci U S A (2013) 1.03
Investigating the purpose of prelamin A processing. Nucleus (2011) 1.01
LMNA cardiomyopathy: cell biology and genetics meet clinical medicine. Dis Model Mech (2011) 1.01
Prenylome profiling reveals S-farnesylation is crucial for membrane targeting and antiviral activity of ZAP long-isoform. Proc Natl Acad Sci U S A (2013) 0.99
Understanding the roles of nuclear A- and B-type lamins in brain development. J Biol Chem (2012) 0.93
Blocking farnesylation of the prelamin A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins. Nucleus (2012) 0.90
Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24. PLoS One (2012) 0.86
Molecular insights into the premature aging disease progeria. Histochem Cell Biol (2016) 0.86
LMNA-associated cardiocutaneous progeria: an inherited autosomal dominant premature aging syndrome with late onset. Am J Med Genet A (2013) 0.85
Nuclear lamins and neurobiology. Mol Cell Biol (2014) 0.84
Embryonic senescence and laminopathies in a progeroid zebrafish model. PLoS One (2011) 0.84
An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo. Cancer Biol Ther (2014) 0.83
Nuclear lamins in the brain - new insights into function and regulation. Mol Neurobiol (2012) 0.82
An absence of nuclear lamins in keratinocytes leads to ichthyosis, defective epidermal barrier function, and intrusion of nuclear membranes and endoplasmic reticulum into the nuclear chromatin. Mol Cell Biol (2014) 0.81
Resveratrol activates SIRT1 in a Lamin A-dependent manner. Cell Cycle (2013) 0.79
Investigation of age-related changes in LMNA splicing and expression of progerin in human skeletal muscles. Int J Clin Exp Pathol (2013) 0.78
Sustained accumulation of prelamin A and depletion of lamin A/C both cause oxidative stress and mitochondrial dysfunction but induce different cell fates. Nucleus (2015) 0.78
Investigation of splicing changes and post-translational processing of LMNA in sporadic inclusion body myositis. Int J Clin Exp Pathol (2013) 0.76
8-Hydroxyquinoline-based inhibitors of the Rce1 protease disrupt Ras membrane localization in human cells. Bioorg Med Chem (2015) 0.76
Mass spectrometry captures off-target drug binding and provides mechanistic insights into the human metalloprotease ZMPSTE24. Nat Chem (2016) 0.75
AIM2 inflammasome is activated by pharmacological disruption of nuclear envelope integrity. Proc Natl Acad Sci U S A (2016) 0.75
Is isoprenylcysteine carboxyl methyltransferase the key to reverse ageing? Front Aging Neurosci (2013) 0.75
What Should the Cardiologist know about Lamin Disease? Arrhythm Electrophysiol Rev (2012) 0.75
Isoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms. Oncogene (2017) 0.75
Shared molecular and cellular mechanisms of premature ageing and ageing-associated diseases. Nat Rev Mol Cell Biol (2017) 0.75
Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature (2003) 12.10
p53 mutant mice that display early ageing-associated phenotypes. Nature (2002) 10.05
Mitotic misregulation and human aging. Science (2000) 8.47
Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem (1996) 8.08
Lamin a truncation in Hutchinson-Gilford progeria. Science (2003) 8.01
Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2004) 7.55
Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med (2008) 5.34
cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins. Proc Natl Acad Sci U S A (1986) 5.07
Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet (1999) 5.04
Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med (2005) 5.01
LMNA mutations in atypical Werner's syndrome. Lancet (2003) 4.81
Genomic instability in laminopathy-based premature aging. Nat Med (2005) 4.54
Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem (1992) 4.20
Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases. Proc Natl Acad Sci U S A (1988) 4.04
Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging. Proc Natl Acad Sci U S A (2006) 3.86
Life at the edge: the nuclear envelope and human disease. Nat Rev Mol Cell Biol (2002) 3.84
The Hutchinson-Gilford progeria syndrome. Report of 4 cases and review of the literature. J Pediatr (1972) 3.79
Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet (2002) 3.78
Aging and genome maintenance: lessons from the mouse? Science (2003) 3.72
Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2005) 3.64
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59
Cellular and molecular mechanisms of action of bisphosphonates. Cancer (2000) 3.57
Protein prenyltransferases. J Biol Chem (1996) 3.52
"Laminopathies": a wide spectrum of human diseases. Exp Cell Res (2007) 3.46
Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med (2008) 3.34
Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature (2005) 3.31
Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci U S A (2005) 3.30
Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci U S A (2002) 3.26
K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem (1997) 3.21
Lamins A and C but not lamin B1 regulate nuclear mechanics. J Biol Chem (2006) 3.02
Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J Lipid Res (2005) 2.88
Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci U S A (2005) 2.85
A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science (2006) 2.71
Human lamin B contains a farnesylated cysteine residue. J Biol Chem (1989) 2.71
Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet (2005) 2.69
Protein prenylation: genes, enzymes, targets, and functions. Annu Rev Genet (1992) 2.58
Distinct structural and mechanical properties of the nuclear lamina in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2006) 2.53
Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum. J Biol Chem (1998) 2.52
Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet (2000) 2.52
New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des (2003) 2.44
Lipodystrophies. Am J Med (2000) 2.44
A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest (2006) 2.39
Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc Natl Acad Sci U S A (2004) 2.39
Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet (2003) 2.36
Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2006) 2.28
The processing pathway of prelamin A. J Cell Sci (1994) 2.25
Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human aging. Proc Natl Acad Sci U S A (2007) 2.24
Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest (2006) 2.23
Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet (2002) 2.20
A lamin A protein isoform overexpressed in Hutchinson-Gilford progeria syndrome interferes with mitosis in progeria and normal cells. Proc Natl Acad Sci U S A (2007) 2.15
The CaaX motif of lamin A functions in conjunction with the nuclear localization signal to target assembly to the nuclear envelope. Cell (1989) 2.12
The role of isoprenylation in membrane attachment of nuclear lamins. A single point mutation prevents proteolytic cleavage of the lamin A precursor and confers membrane binding properties. J Cell Sci (1994) 2.10
Evidence for modification of lamin B by a product of mevalonic acid. J Biol Chem (1988) 2.09
The nuclear envelope, muscular dystrophy and gene expression. Trends Cell Biol (2000) 2.06
Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursors. Hum Mol Genet (2005) 2.06
Homozygous and compound heterozygous mutations in ZMPSTE24 cause the laminopathy restrictive dermopathy. J Invest Dermatol (2005) 2.06
Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina. Proc Natl Acad Sci U S A (1992) 2.05
Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2005) 2.05
A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci U S A (2008) 2.02
Fluorimetric evaluation of the affinities of isoprenylated peptides for lipid bilayers. Biochemistry (1994) 1.99
Maturation of nuclear lamin A involves a specific carboxy-terminal trimming, which removes the polyisoprenylation site from the precursor; implications for the structure of the nuclear lamina. FEBS Lett (1989) 1.97
Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy. Hum Mol Genet (2004) 1.94
Isoprenylation is required for the processing of the lamin A precursor. J Cell Biol (1990) 1.90
Genome-scale expression profiling of Hutchinson-Gilford progeria syndrome reveals widespread transcriptional misregulation leading to mesodermal/mesenchymal defects and accelerated atherosclerosis. Aging Cell (2004) 1.87
Prelamin A endoproteolytic processing in vitro by recombinant Zmpste24. Biochem J (2005) 1.83
DNA damage responses in progeroid syndromes arise from defective maturation of prelamin A. J Cell Sci (2006) 1.80
Incorporation of a product of mevalonic acid metabolism into proteins of Chinese hamster ovary cell nuclei. J Cell Biol (1988) 1.78
Nuclear envelope alterations in fibroblasts from patients with muscular dystrophy, cardiomyopathy, and partial lipodystrophy carrying lamin A/C gene mutations. Muscle Nerve (2004) 1.73
Cloning and characterization of a mammalian prenyl protein-specific protease. J Biol Chem (1999) 1.68
Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors. J Cell Sci (2006) 1.65
Development of bisphosphonates. Breast Cancer Res (2001) 1.63
Biochemical studies of Zmpste24-deficient mice. J Biol Chem (2001) 1.61
Smooth muscle cell depletion and collagen types in progeric arteries. Cardiovasc Pathol (2001) 1.53
Histological and ultrastructural features of atherosclerosis in progeria. Cardiovasc Pathol (2000) 1.48
New approaches to progeria. Pediatrics (2007) 1.47
Lethal neonatal Hutchinson-Gilford progeria syndrome. Am J Med Genet (1999) 1.44
Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated. J Clin Invest (2008) 1.40
Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS (2003) 1.40
Bisphosphonate mechanism of action. Curr Rheumatol Rep (2003) 1.39
Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence. Cell Death Differ (2007) 1.38
Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. Biochim Biophys Acta (2007) 1.33
The truncated prelamin A in Hutchinson-Gilford progeria syndrome alters segregation of A-type and B-type lamin homopolymers. Hum Mol Genet (2006) 1.32
The A-type lamins: nuclear structural proteins as a focus for muscular dystrophy and cardiovascular diseases. Trends Cardiovasc Med (2001) 1.28
From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int (2004) 1.26
Compound heterozygous ZMPSTE24 mutations reduce prelamin A processing and result in a severe progeroid phenotype. J Med Genet (2005) 1.25
Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol (2003) 1.23
Correction of cellular phenotypes of Hutchinson-Gilford Progeria cells by RNA interference. Hum Genet (2005) 1.22
HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells. Proc Natl Acad Sci U S A (2007) 1.20
A homozygous ZMPSTE24 null mutation in combination with a heterozygous mutation in the LMNA gene causes Hutchinson-Gilford progeria syndrome (HGPS): insights into the pathophysiology of HGPS. Hum Mutat (2006) 1.20
Biochemistry of protein prenylation. J Lipid Res (1992) 1.14
Mutation analysis of the lamin A/C gene (LMNA) among patients with different cardiomuscular phenotypes. J Med Genet (2003) 1.13
Targeted transgenic expression of the mutation causing Hutchinson-Gilford progeria syndrome leads to proliferative and degenerative epidermal disease. J Cell Sci (2008) 1.12
Hutchinson-Gilford progeria syndrome: a pathologic study. Pediatr Pathol Mol Med (2002) 1.12
Compound heterozygosity for mutations in LMNA causes a progeria syndrome without prelamin A accumulation. Hum Mol Genet (2006) 1.11
Hutchinson-Gilford progeria syndrome: report of a Libyan family and evidence of autosomal recessive inheritance. Clin Genet (1989) 1.10
Lamin B methylation and assembly into the nuclear envelope. J Biol Chem (1989) 1.10
Eliminating the synthesis of mature lamin A reduces disease phenotypes in mice carrying a Hutchinson-Gilford progeria syndrome allele. J Biol Chem (2008) 1.09
A carboxyl-terminal interaction of lamin B1 is dependent on the CAAX endoprotease Rce1 and carboxymethylation. J Cell Biol (2003) 1.08
Subcellular localization and partial purification of prelamin A endoprotease: an enzyme which catalyzes the conversion of farnesylated prelamin A to mature lamin A. FEBS Lett (1999) 1.07
Bisphosphonates in osteoporosis. Eur Spine J (2003) 1.05
The knockout mouse project. Nat Genet (2004) 7.80
Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab (2007) 5.04
BayGenomics: a resource of insertional mutations in mouse embryonic stem cells. Nucleic Acids Res (2003) 4.83
A public gene trap resource for mouse functional genomics. Nat Genet (2004) 3.96
Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a. Cell Metab (2011) 3.49
The International Gene Trap Consortium Website: a portal to all publicly available gene trap cell lines in mouse. Nucleic Acids Res (2006) 3.40
Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci U S A (2005) 3.30
ESCRT-III dysfunction causes autophagosome accumulation and neurodegeneration. Curr Biol (2007) 3.27
Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci U S A (2002) 3.26
Lamins A and C but not lamin B1 regulate nuclear mechanics. J Biol Chem (2006) 3.02
Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler Thromb Vasc Biol (2009) 2.99
Laminopathies and the long strange trip from basic cell biology to therapy. J Clin Invest (2009) 2.94
Lamin B1 is required for mouse development and nuclear integrity. Proc Natl Acad Sci U S A (2004) 2.89
Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J Lipid Res (2005) 2.88
Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci U S A (2005) 2.85
GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab (2010) 2.75
A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science (2006) 2.71
A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest (2006) 2.39
Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc Natl Acad Sci U S A (2004) 2.39
Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest (2006) 2.23
Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation (2009) 2.20
Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation (2006) 2.13
GPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons. Curr Opin Lipidol (2007) 2.01
Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J Lipid Res (2008) 1.91
The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons. J Biol Chem (2008) 1.91
Functional coupling between the extracellular matrix and nuclear lamina by Wnt signaling in progeria. Dev Cell (2010) 1.90
Abnormal development of the cerebral cortex and cerebellum in the setting of lamin B2 deficiency. Proc Natl Acad Sci U S A (2010) 1.89
Chordin-like CR domains and the regulation of evolutionarily conserved extracellular signaling systems. Gene (2002) 1.88
Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria. Science (2013) 1.88
Deficiencies in lamin B1 and lamin B2 cause neurodevelopmental defects and distinct nuclear shape abnormalities in neurons. Mol Biol Cell (2011) 1.86
Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. Mol Biol Cell (2005) 1.85
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J Clin Invest (2004) 1.81
Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation (2011) 1.79
Abnormal patterns of lipoprotein lipase release into the plasma in GPIHBP1-deficient mice. J Biol Chem (2008) 1.73
Chylomicronemia elicits atherosclerosis in mice--brief report. Arterioscler Thromb Vasc Biol (2009) 1.72
Crossveinless-2 Is a BMP feedback inhibitor that binds Chordin/BMP to regulate Xenopus embryonic patterning. Dev Cell (2008) 1.69
Agpat6 deficiency causes subdermal lipodystrophy and resistance to obesity. J Lipid Res (2006) 1.68
Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation (2003) 1.68
Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia. J Lipid Res (2009) 1.67
Differential membrane localization of ERas and Rheb, two Ras-related proteins involved in the phosphatidylinositol 3-kinase/mTOR pathway. J Biol Chem (2005) 1.64
Agpat6--a novel lipid biosynthetic gene required for triacylglycerol production in mammary epithelium. J Lipid Res (2006) 1.62
Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects. Circ Cardiovasc Genet (2010) 1.60
A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc Natl Acad Sci U S A (2005) 1.59
Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol Cell Biol (2002) 1.56
Apobec-1 protects intestine from radiation injury through posttranscriptional regulation of cyclooxygenase-2 expression. Gastroenterology (2004) 1.56
Highly conserved cysteines within the Ly6 domain of GPIHBP1 are crucial for the binding of lipoprotein lipase. J Biol Chem (2009) 1.54
AGPAT6 is a novel microsomal glycerol-3-phosphate acyltransferase. J Biol Chem (2008) 1.50
CD1d function is regulated by microsomal triglyceride transfer protein. Nat Med (2004) 1.49
Disruption of the phosphatidylserine decarboxylase gene in mice causes embryonic lethality and mitochondrial defects. J Biol Chem (2005) 1.48
GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J Clin Invest (2007) 1.47
Prelamin A farnesylation and progeroid syndromes. J Biol Chem (2006) 1.43
Compensatory increase in hepatic lipogenesis in mice with conditional intestine-specific Mttp deficiency. J Biol Chem (2005) 1.43
Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated. J Clin Invest (2008) 1.40
Mouse models of the laminopathies. Exp Cell Res (2007) 1.40
Normal binding of lipoprotein lipase, chylomicrons, and apo-AV to GPIHBP1 containing a G56R amino acid substitution. Biochim Biophys Acta (2007) 1.39
Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation (2004) 1.37
An absence of both lamin B1 and lamin B2 in keratinocytes has no effect on cell proliferation or the development of skin and hair. Hum Mol Genet (2011) 1.35
ATP-citrate lyase deficiency in the mouse. J Biol Chem (2003) 1.35
Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes. Hum Mutat (2007) 1.34
Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. Biochim Biophys Acta (2007) 1.33
An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. Hum Mol Genet (2010) 1.26
Regulation of prelamin A but not lamin C by miR-9, a brain-specific microRNA. Proc Natl Acad Sci U S A (2012) 1.26
Direct synthesis of lamin A, bypassing prelamin a processing, causes misshapen nuclei in fibroblasts but no detectable pathology in mice. J Biol Chem (2010) 1.24
The expression of GPIHBP1, an endothelial cell binding site for lipoprotein lipase and chylomicrons, is induced by peroxisome proliferator-activated receptor-gamma. Mol Endocrinol (2008) 1.23